CAR T cells may be a particularly attractive option in ACC given the high level of chemoresistance; however, CAR T cells generally have more toxicity than ADCs51, and thus, it may be advisable to accrue safety information on targeting DLK1 from our phase 1 study before pursuing clinical testing of CAR T cells. Here, DLK1 is linked to adrenal cortex carcinoma.